Vioxx debacle: A class effect?

October 6, 2004

NEJM with two early release articles. One by cardiologist Eric Topol, and the other questioning whether Celebrex and other COX-2’s have similar cardiovascular risk.



Related posts:

  1. Topol on Russert
  2. The left-leaning NEJM
  3. COURAGE trial: The NEJM strikes back
  4. Primary care: "Second class citizens"
  5. Does aspirin prevent fatal heart attack and stroke?
  6. Stents and the COURAGE trial


KevinMD.com on Facebook


Comments on this entry are closed.

Previous post: The repercussions of the flu vaccine shortage

Next post: CNN news, brought to you by Ambien

Site Meter